Rhythm Bio enters ColoSTAT agreement with 4Cyte Pathology
Filed with ASX · · 5 pages · English
✓ Rhythm has entered into a non-exclusive ColoSTAT® Product Distribution Service Agreement with 4Cyte Pathology, one of Australia’s largest independent pathology providers. ✓ 4Cyte will integrate ColoSTAT® into its clinical ordering system across its network of over 1,000 patient collection centres in New South Wales, Victoria, and Queensland. ✓ 4Cyte will support patient sample collection through
Rhythm Biosciences Limited on 6ix
In the deck
Story so far
Earlier from Rhythm Biosciences
- ColoSTAT commercial deployment - First physician enrolled
- Rhythm Biosciences Signs Manufacturing Agreement
- Quarterly Activities Report and Appendix 4C
- Enhanced Genetype colorectal cancer risk test released - supports earlier disease detection and ColoSTAT® targeting
- datma and Rhythm Biosciences Announce Collaboration to Apply Federated Real-World Data to Genomic Diagnostic Development
Later from Rhythm Biosciences
- Half-Year Financial Report and Appendix 4D
- Trading Halt
- Exercise of RHYO Options underwritten for $4.5m to $6.0m
- RHY Executes SE Asian Genetype Distribution Agreement
- NATA Accredits ColoSTAT Clinical Testing Service
Follow Rhythm Biosciences into a list and get an email when it puts out news.
Follow Rhythm Biosciences